Aptus Pharma Ltd

Aptus Pharma Preferential Issue

Aptus Pharma got BSE in-principle approval for a preferential issue of 15,99,270 shares at a minimum Rs. 280 each. The issue is worth about Rs. 44.78 Crore.

Value

₹44.78 Cr

Aptus Pharma Investor Presentation: Key Takeaways

H1 FY27 revenue ₹48.92 Cr, EBITDA ₹7.68 Cr (15.7% margin), PAT ₹5.07 Cr; revenue exceeds full FY26 (₹46.57 Cr). Trading-heavy model with rising receivables and negative operating cash flow.

Aptus Pharma H1 FY27 Results: Net Profit ₹5.1 Cr, Up 200.0% YoY

Aptus Pharma Ltd reported revenue from operations of ₹48.9 Cr (+239.6% YoY) and net profit of ₹5.1 Cr (+200.0% YoY) for H1 FY27.

Key figure

Net profit ₹5.1 Cr · +200.0% YoY